Jaskaran Singh

13.1k total citations · 5 hit papers
94 papers, 8.1k citations indexed

About

Jaskaran Singh is a scholar working on Pharmacology, Psychiatry and Mental health and Biological Psychiatry. According to data from OpenAlex, Jaskaran Singh has authored 94 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Pharmacology, 31 papers in Psychiatry and Mental health and 29 papers in Biological Psychiatry. Recurrent topics in Jaskaran Singh's work include Treatment of Major Depression (60 papers), Tryptophan and brain disorders (29 papers) and Schizophrenia research and treatment (15 papers). Jaskaran Singh is often cited by papers focused on Treatment of Major Depression (60 papers), Tryptophan and brain disorders (29 papers) and Schizophrenia research and treatment (15 papers). Jaskaran Singh collaborates with scholars based in United States, Belgium and United Kingdom. Jaskaran Singh's co-authors include Husseini K. Manji, Carlos A. Zarate, David A. Luckenbaugh, Dennis S. Charney, Paul J. Carlson, Rezvan Ameli, Nancy E. Brutsché, Wayne C. Drevets, Ella Daly and Pilar Lim and has published in prestigious journals such as American Journal of Psychiatry, Scientific Reports and Biological Psychiatry.

In The Last Decade

Jaskaran Singh

88 papers receiving 7.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression

2006 2.7k citations Carlos A. Zarate, Jaskaran Singh et al. profile →
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression

2017 489 citations Ella Daly, Jaskaran Singh et al. JAMA Psychiatry profile →
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study

2019 483 citations Vanina Popova, Ella Daly et al. American Journal of Psychiatry profile →
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study

2018 357 citations Jaskaran Singh, Maggie Fedgchin et al. American Journal of Psychiatry profile →
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)

2019 297 citations Maggie Fedgchin, Madhukar H. Trivedi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jaskaran Singh United States	31	5.2k	4.1k	2.5k	2.1k	1.2k	94	8.1k
Nancy E. Brutsché United States	29	6.0k 1.1×	4.9k 1.2×	2.8k 1.1×	1.4k 0.7×	1.5k 1.3×	34	7.8k
Amit Anand United States	37	3.0k 0.6×	2.5k 0.6×	2.5k 1.0×	1.9k 0.9×	2.7k 2.3×	127	8.1k
Sanjay J. Mathew United States	54	6.2k 1.2×	5.3k 1.3×	3.0k 1.2×	2.0k 1.0×	2.3k 2.0×	186	11.3k
Rodrigo Machado‐Vieira United States	60	3.3k 0.6×	4.7k 1.1×	2.7k 1.1×	4.1k 2.0×	1.4k 1.2×	191	11.2k
Daniel Souery Belgium	44	2.5k 0.5×	2.1k 0.5×	890 0.4×	2.2k 1.1×	825 0.7×	206	6.7k
Nancy Diazgranados United States	25	2.6k 0.5×	2.2k 0.5×	1.3k 0.5×	1.2k 0.6×	745 0.6×	79	4.5k
Dan A. Oren United States	30	2.5k 0.5×	2.1k 0.5×	1.9k 0.7×	1.1k 0.5×	754 0.7×	73	5.5k
Allison C. Nugent United States	43	1.9k 0.4×	1.6k 0.4×	1.6k 0.6×	1.4k 0.7×	2.6k 2.2×	109	6.1k
Ioline D. Henter United States	40	1.9k 0.4×	2.0k 0.5×	1.2k 0.5×	1.4k 0.7×	531 0.5×	81	4.8k
Mark J. Niciu United States	38	2.2k 0.4×	1.9k 0.5×	1.1k 0.4×	702 0.3×	880 0.8×	66	4.3k

Countries citing papers authored by Jaskaran Singh

Since Specialization

Citations

This map shows the geographic impact of Jaskaran Singh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaskaran Singh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaskaran Singh more than expected).

Fields of papers citing papers by Jaskaran Singh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaskaran Singh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaskaran Singh. The network helps show where Jaskaran Singh may publish in the future.

Co-authorship network of co-authors of Jaskaran Singh

This figure shows the co-authorship network connecting the top 25 collaborators of Jaskaran Singh. A scholar is included among the top collaborators of Jaskaran Singh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaskaran Singh. Jaskaran Singh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wazid, Mohammad, et al.. (2024). An effective intrusion detection scheme for Distributed Network Protocol 3 (DNP3) applied in SCADA-enabled IoT applications. Computers & Electrical Engineering. 120. 109828–109828. 2 indexed citations

Jamieson, Carol, Vanina Popova, Ella Daly, et al.. (2023). Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant. Health and Quality of Life Outcomes. 21(1). 40–40. 7 indexed citations

Singh, Jaskaran, et al.. (2023). Effect of Microdissection of Inferior Thyroid Artery on Post-operative Hypocalcemia in Total Thyroidectomy. Indian Journal of Otolaryngology and Head & Neck Surgery. 75(3). 1461–1468.

Turkoz, Ibrahim, Ella Daly, Jaskaran Singh, et al.. (2021). Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response. The Journal of Clinical Psychiatry. 82(4). 17 indexed citations

Ochs-Ross, Rachel, Ewa Wajs, Ella Daly, et al.. (2021). Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study. American Journal of Geriatric Psychiatry. 30(5). 541–556. 27 indexed citations

Hudgens, Stacie, Lysbeth Floden, Carol Jamieson, et al.. (2020). Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant. Journal of Affective Disorders. 281. 767–775. 45 indexed citations

Morrison, Robert M., Jaskaran Singh, Ella Daly, et al.. (2019). Effect of esketamine nasal spray on cognition in patients with treatment-resistant depression: results from five phase-3 studies. European Neuropsychopharmacology. 29. 1 indexed citations

Popova, Vanina, Ella Daly, Madhukar H. Trivedi, et al.. (2019). Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. American Journal of Psychiatry. 176(6). 428–438. 483 indexed citations breakdown →

Lewis, Sandy, Carla DeMuro, Geert De Bruecker, et al.. (2019). Analysis of Clinical Trial Exit Interview Data in Patients with Treatment-Resistant Depression. Patient. 12(5). 527–537. 10 indexed citations

10.

Turkoz, Ibrahim, Wing Chow, Larry Alphs, et al.. (2018). Interpretation of Change In Patient-Reported Outcomes in Treatment-Resistant Depression. Value in Health. 21. S187–S187. 1 indexed citations

11.

Fife, Daniel, et al.. (2018). Treatment resistant depression incidence estimates from studies of health insurance databases depend strongly on the details of the operating definition. Heliyon. 4(7). e00707–e00707. 15 indexed citations

12.

Daly, Ella, Jaskaran Singh, Maggie Fedgchin, et al.. (2017). Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression. JAMA Psychiatry. 75(2). 139–139. 489 indexed citations breakdown →

13.

Gopal, Srihari, Rosanne Lane, Isaac Nuamah, et al.. (2017). Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter Study. CNS Drugs. 31(9). 797–808. 9 indexed citations

14.

Fife, Daniel, Yu Feng, Chee‐Jen Chang, et al.. (2017). Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan. Psychiatry Research. 252. 277–283. 44 indexed citations

15.

Rotroff, Daniel M., Daniel Corum, Alison A. Motsinger‐Reif, et al.. (2016). Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants. Translational Psychiatry. 6(9). e894–e894. 78 indexed citations

16.

Kent, Justine, David Hough, Jaskaran Singh, Keith Karcher, & Gahan Pandina. (2013). An Open-Label Extension Study of the Safety and Efficacy of Risperidone in Children and Adolescents with Autistic Disorder. Journal of Child and Adolescent Psychopharmacology. 23(10). 676–686. 33 indexed citations

17.

Kent, Justine, Stuart Kushner, Xiaoping Ning, et al.. (2012). Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study. Journal of Autism and Developmental Disorders. 43(8). 1773–1783. 87 indexed citations

18.

Alphs, Larry, Srihari Gopal, Keith Karcher, et al.. (2011). Are the Long-Acting Intramuscular Formulations of Risperidone or Paliperidone Palmitate Associated with Post-Injection Delirium/Sedation Syndrome? An Assessment of Safety Databases. Current Drug Safety. 6(1). 43–45. 15 indexed citations

19.

Zarate, Carlos A., Jaskaran Singh, Jorge A. Quiroz, et al.. (2006). A Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression. American Journal of Psychiatry. 163(1). 153–155. 310 indexed citations

20.

Singh, Jaskaran & Carlos A. Zarate. (2006). Pharmacological treatment of psychiatric comorbidity in bipolar disorder: a review of controlled trials. Bipolar Disorders. 8(6). 696–709. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact